Janssen Pharmaceuticals announced today the FDA has approved Invega Trinza, a three-month long-acting atypical antipsychotic, under priority review for the New Drug Application for treatment of schizophrenia.In a longitudinal maintenance trial, 93% of patients who received Invega Trinza (3-month palperidone palmitate) did not experience a significant return of schizophrenia symptoms. The phase 3 study findings indicated had comparable safety and tolerability to Invega Sustenna (1-month paliperidone palmitate, Janssen Pharmaceuticals).
No comments:
Post a Comment